German life science enterprise Bayer has officially announced that the European Medicines Agency (EMA) has validated and initiated its centralized review procedure for the marketing authorization application (MAA) of asundexian. The regulatory submission stands as the historic first marketing authorization filing for an oral Factor XIa (FXIa) inhibitor within the European territory, targeted specifically at the secondary prevention of ischemic stroke in adult patients presenting with a prior non-cardioembolic ischemic stroke or a high-risk transient ischemic attack (TIA).
The documented clinical data profiles from the OCEANIC-STROKE trial, regional epidemiological burdens, and corporate financial metrics feature:
-
Efficacy and Safety Readouts From the Phase III OCEANIC-STROKE Trial:
-
Trial Architecture: The pivotal Phase III OCEANIC-STROKE study operated as a multicenter, international, randomized, placebo-controlled, double-blind, parallel-group, event-driven trial that randomized 12,327 participants worldwide. The protocol evaluated the therapeutic performance of oral asundexian 50 mg administered once-daily in combination with standard antiplatelet therapy, benchmarked against a placebo control arm. The comprehensive clinical datasets have been formally published in The New England Journal of Medicine.
-
Profound Stroke Risk Reduction: The final analysis demonstrated that asundexian 50 mg achieved a statistically significant 26% reduction in recurrent ischemic stroke events among patients following a non-cardioembolic ischemic stroke or high-risk TIA compared to the placebo cohort (with both groups maintaining concurrent background antiplatelet regimens).
-
Favorable Bleeding Profiles: Crucially, this optimization of efficacy was achieved with zero increase in major bleeding events as quantified by the International Society on Thrombosis and Hemostasis (ISTH) criteria. Mechanistically, while FXIa is a primary driver in pathological thrombus growth and vessel occlusion, it plays only a minor role in maintaining physiological hemostasis at sites of vascular injury. At present, asundexian remains an investigational compound and retains zero commercial approvals by any global health authority.
-
-
Macro Epidemiological Burdens of Cerebrovascular Pathology in Europe:
-
Stroke continues to rank as the second leading cause of mortality both across Europe and on a global scale. Approximately 10 million European citizens are currently living with the long-term debilitating consequences of stroke, while more than one million individuals are newly impacted by the disease annually. Financially, this pathology imposes a massive macroeconomic strain, with estimated global healthcare costs scaling to $891 billion annually.
-
Between the historical baselines of 2010 and 2019, the prevalence of ischemic stroke and stroke-related mortality surged by 4% and 7%, respectively, across EU member states. To mitigate this expanding public health crisis, Bayer is aggressively advancing parallel regulatory files worldwide; both China’s Center for Drug Evaluation (CDE) and the U.S. Food and Drug Administration (FDA) have recently granted Priority Review designations to the asundexian pipeline.
-
-
Corporate Scale and R&D Reinvestment Parameters of Bayer AG:
-
In fiscal year 2025, the global Bayer holding group maintained a consolidated workforce of approximately 88,000 personnel worldwide, generating annual net revenues of 45.6 billion euros.
-
To fortify its market leadership within the cardiology and neurology therapeutic spaces and generate long-term innovation value, the enterprise deployed a massive annual research and development (R&D) expenditure tranche of 5.8 billion euros over the 2025 fiscal period.
-